Internal Neuromodulation

Internal Neuromodulation Market Outlook

The global internal neuromodulation market is poised for significant growth, projected to reach USD 11.30 billion by 2035, expanding at a compound annual growth rate (CAGR) of 10.5% during the forecast period from 2025 to 2035. The increasing prevalence of neurological disorders, rising incidences of chronic pain, and a growing geriatric population are key factors driving the market growth. Additionally, technological advancements in neuromodulation devices, coupled with a surge in awareness regarding non-pharmacological treatments, are further propelling the adoption of these therapeutic options. Moreover, favorable reimbursement policies and increased investment in research and development activities by leading healthcare companies are expected to foster the market expansion, thereby enhancing the quality of life for patients suffering from debilitating conditions.

Growth Factor of the Market

The internal neuromodulation market is experiencing a robust growth phase due to several critical factors. First and foremost, the rising prevalence of chronic pain conditions such as neuropathic pain and back pain necessitates effective management solutions, leading to an increased demand for neuromodulation therapies. Furthermore, advancements in technology, including the development of more sophisticated and minimally invasive devices, are attracting both healthcare providers and patients, thereby expanding the market. The growing acceptance of neuromodulation as a viable alternative to traditional pain management techniques such as opioid medications has also contributed significantly to market growth. Additionally, increased funding for research activities in neurological health has resulted in novel product developments, which are further expected to enhance market dynamics. Lastly, the expansion of healthcare infrastructure and improved access to treatment options in emerging economies are also anticipated to boost the growth of the internal neuromodulation market.

Key Highlights of the Market

• The internal neuromodulation market is estimated to grow at a CAGR of 10.5% from 2025 to 2035.
• Technological advancements in device design are driving market innovation and adoption.
• Chronic pain management is the largest application segment, reflecting the high demand for effective treatment options.
• North America holds the largest market share, driven by advanced healthcare infrastructure and high healthcare expenditure.
• Emerging markets in Asia Pacific and Latin America present significant growth opportunities for market players.

By Product Type

Spinal Cord Stimulators:

Spinal Cord Stimulators (SCS) are widely recognized for their efficacy in managing chronic pain, especially in patients who have not responded to conventional therapies. These devices work by delivering electrical impulses to the spinal cord, effectively interrupting pain signals before they reach the brain. The increasing acceptance of SCS for various pain conditions, including failed back surgery syndrome, is driving their adoption. Additionally, advancements in SCS technology, such as the development of wireless and rechargeable systems, are making these devices more appealing to both patients and healthcare providers. With ongoing research and clinical trials highlighting their benefits, spinal cord stimulators are expected to dominate the internal neuromodulation market in the coming years.

Deep Brain Stimulators:

Deep Brain Stimulators (DBS) represent a critical segment of the internal neuromodulation market, primarily used for the treatment of movement disorders such as Parkinson's disease and essential tremors. These devices work by delivering electrical stimulation to specific brain regions, significantly improving motor function and quality of life for patients. The growing prevalence of neurological disorders, coupled with increasing awareness regarding the benefits of DBS, is driving market growth. Furthermore, ongoing advancements in DBS technology, including the development of adaptive stimulation systems and improvements in device longevity, are anticipated to enhance their effectiveness and expand their application scope, solidifying their position in the market.

Vagus Nerve Stimulators:

Vagus Nerve Stimulators (VNS) are gaining traction within the internal neuromodulation market due to their application in treating epilepsy and depression. These devices work by sending electrical impulses to the vagus nerve, which in turn modulates brain activity. The increasing incidence of treatment-resistant epilepsy and major depressive disorder is driving the demand for VNS therapy. Moreover, the growing body of evidence supporting the efficacy of VNS in improving patients’ quality of life is further boosting its adoption. As research progresses and more indications for VNS emerge, this segment is likely to experience significant growth in the coming years.

Sacral Nerve Stimulators:

Sacral Nerve Stimulators (SNS) are primarily utilized for managing urinary incontinence and fecal incontinence. These devices function by stimulating the sacral nerves, which control the bladder and bowel functions. The increasing prevalence of urinary disorders, particularly among the aging population, is driving the demand for SNS therapies. Additionally, the minimally invasive nature of sacral nerve stimulation procedures appeals to patients looking for effective solutions without resorting to major surgeries. As awareness of these innovative treatments grows and more clinical evidence emerges, the sacral nerve stimulator segment is expected to grow steadily within the internal neuromodulation market.

Gastric Electrical Stimulators:

Gastric Electrical Stimulators (GES) are emerging as essential devices for managing gastroparesis, a condition that affects the normal spontaneous movement of the muscles in the stomach. These devices deliver electrical impulses to the stomach muscles, enhancing gastric emptying and improving symptoms associated with gastroparesis. With increasing rates of diabetes—one of the primary causes of gastroparesis—there is a rising demand for effective treatment options like GES. The successful integration of GES into patient care pathways, along with growing awareness among healthcare providers, positions this product segment for substantial growth in the internal neuromodulation market.

By Application

Chronic Pain Management:

Chronic pain management stands as one of the largest application segments within the internal neuromodulation market. The increasing prevalence of chronic pain conditions across various demographics is a significant driving force behind the growth in this area. Many patients suffering from conditions such as arthritis, fibromyalgia, and neuropathic pain are turning to neuromodulation therapies when traditional pain management approaches fail. Spinal cord stimulators are commonly employed in this domain, and ongoing research into optimizing these therapies continues to drive advancements. The demand for effective chronic pain management solutions is expected to fuel the growth of the internal neuromodulation market significantly.

Parkinson's Disease:

The internal neuromodulation market is increasingly focused on applications for Parkinson's disease, a neurodegenerative disorder affecting millions globally. Deep brain stimulation is particularly effective in alleviating the symptoms associated with Parkinson's, such as tremors, rigidity, and bradykinesia. As the global population ages and the prevalence of Parkinson's disease rises, the demand for neuromodulation therapies is expected to grow. Furthermore, ongoing research into the long-term benefits and safety of deep brain stimulation for Parkinson's patients enhances the appeal of this treatment option, contributing to the segment's expansion within the internal neuromodulation market.

Epilepsy:

Epilepsy is another significant application area for internal neuromodulation, with vagus nerve stimulation emerging as a promising treatment for drug-resistant epilepsy patients. The increasing recognition of VNS as an adjunctive therapy for controlling seizures is driving demand within this segment. As more healthcare providers become aware of the efficacy and safety of vagus nerve stimulators, the market is expected to witness robust growth. Additionally, ongoing advancements in device technology and clinical research supporting VNS therapy are likely to facilitate greater adoption of this treatment option among patients suffering from epilepsy.

Urinary Incontinence:

Urinary incontinence is a prevalent condition affecting a significant portion of the population, particularly women. Sacral nerve stimulation has emerged as a viable treatment option for patients who do not respond to conservative management strategies. As awareness of the psychological and social impacts of urinary incontinence increases, more patients are seeking effective solutions. The effectiveness of sacral nerve stimulators in improving bladder control has positioned them favorably in the internal neuromodulation market. As healthcare providers continue to recognize the benefits of this technology, the segment is likely to see considerable growth in the coming years.

Gastroparesis:

Gastroparesis is a condition characterized by delayed gastric emptying, greatly impacting patients' quality of life. Gastric electrical stimulators serve as an innovative solution for managing this condition, providing symptomatic relief for patients who are often resistant to conventional treatments. The growing incidence of gastroparesis, primarily associated with diabetes, is driving the demand for effective therapies in this area. As clinical evidence supporting the efficacy of gastric electrical stimulation continues to expand, this application segment within the internal neuromodulation market is expected to grow significantly.

By Distribution Channel

Hospitals:

Hospitals are the primary distribution channel for internal neuromodulation devices, as they are equipped with advanced infrastructure and specialized personnel to perform the required procedures safely and effectively. The availability of comprehensive patient care and multidisciplinary teams allows hospitals to provide optimal treatment options for patients requiring neuromodulation therapies. Additionally, hospitals often collaborate with medical device manufacturers, ensuring access to the latest technologies and methodologies. As the prevalence of neurological disorders continues to rise, the hospital segment is expected to maintain a significant share of the internal neuromodulation market.

Specialty Clinics:

Specialty clinics that focus on pain management and neurology are increasingly becoming important distribution channels for internal neuromodulation therapies. These clinics offer tailored services to patients, often providing a more personalized and comprehensive approach to treatment. The growing preference for specialized care among patients leads to increased demand for therapies like spinal cord stimulators and deep brain stimulators. Moreover, as patients seek alternatives to traditional pain management techniques, specialty clinics are likely to experience growth, contributing positively to the internal neuromodulation market.

Ambulatory Surgical Centers:

Ambulatory Surgical Centers (ASCs) play a crucial role in the distribution of internal neuromodulation therapies, offering minimally invasive procedures with shorter recovery times. These centers are becoming increasingly popular as patients and healthcare providers recognize the benefits of outpatient care. The rising number of ASCs and advancements in surgical techniques are allowing for more neuromodulation procedures to be performed outside of traditional hospital settings. As the demand for cost-effective and efficient surgical options grows, the ASC segment is expected to expand its share within the internal neuromodulation market.

Research Institutes:

Research institutes are vital distribution channels for internal neuromodulation devices, as they are often at the forefront of innovation and clinical trials. These institutes not only contribute to the development of new technologies but also facilitate the evaluation and validation of existing therapies. As more neuromodulation devices undergo clinical testing and validation, research institutes play a pivotal role in shaping market trends and guiding regulatory approvals. The collaboration between research institutes and industry players is expected to drive advancements in the internal neuromodulation market.

Online Sales:

Online sales channels are becoming increasingly relevant in the internal neuromodulation market, providing alternative methods for manufacturers to reach patients and healthcare providers. The convenience, accessibility, and wealth of information available online empower patients to explore their treatment options and make informed decisions. Additionally, the growing trend of telehealth and remote monitoring is facilitating online sales of neuromodulation devices. As digital health solutions continue to gain traction, the online sales channel is expected to contribute significantly to market growth in the internal neuromodulation sector.

By Ingredient Type

Titanium:

Titanium is a widely used material in the manufacturing of internal neuromodulation devices due to its biocompatibility and strength. Its resistance to corrosion and ability to integrate well with human tissue makes it an ideal choice for various applications, including spinal cord stimulators and deep brain stimulators. The demand for titanium-based devices is driven by the increasing focus on patient safety and the need for durable and reliable materials in medical devices. As manufacturers continue to prioritize high-quality materials in their product designs, titanium is expected to maintain a significant presence in the internal neuromodulation market.

Stainless Steel:

Stainless steel is another essential ingredient type utilized in internal neuromodulation devices, particularly in the construction of leads and electrodes. Its durability and resistance to wear make it an ideal choice for devices that require long-term implantation in the body. The increasing demand for effective and reliable neuromodulation therapies is driving the need for stainless steel components in device manufacturing. As healthcare providers and patients prioritize longevity and safety in their treatment options, stainless steel is likely to remain a fundamental ingredient in the internal neuromodulation market.

Silicone:

Silicone is widely used in internal neuromodulation devices, particularly for insulation and casing materials, due to its flexibility and biocompatibility. The use of silicone helps enhance the overall performance and safety of devices by minimizing the risk of adverse reactions within the human body. As market players continue to focus on the development of advanced and patient-friendly devices, silicone is expected to play a vital role in the internal neuromodulation market. The growing emphasis on user comfort and device longevity supports the continued demand for silicone in product design.

Lead:

Leads are critical components of internal neuromodulation devices, as they facilitate the delivery of electrical signals to targeted areas of the nervous system. The increasing adoption of neuromodulation therapies for various applications is driving the demand for high-quality leads that offer reliability and performance. As manufacturers invest in research and development to improve lead technology, the need for effective and durable leads is expected to grow in tandem with the internal neuromodulation market. Innovations in lead design and manufacturing processes will enhance the efficacy of neuromodulation therapies, further solidifying their significance in this segment.

Lithium:

Lithium batteries are commonly employed in internal neuromodulation devices to ensure robust and long-lasting power supply. The increasing reliance on battery-operated devices, especially as technology advances towards more compact and efficient designs, is driving the demand for lithium-based power solutions. With the focus on minimizing device size while maximizing performance, lithium batteries offer a suitable option for powering neuromodulation devices safely and effectively. As the market continues to evolve, the importance of lithium as an ingredient type within the internal neuromodulation sector is anticipated to increase significantly.

By Region

Regional analysis of the internal neuromodulation market reveals significant disparities, with North America leading the market share, primarily due to advanced healthcare infrastructure, high healthcare expenditure, and widespread acceptance of neuromodulation therapies. The North American internal neuromodulation market is projected to grow at a CAGR of approximately 11% during the forecast period, driven by the increasing prevalence of chronic pain and neurological disorders. The presence of established players and ongoing investment in research and development further bolster the region's market position. Additionally, favorable reimbursement policies and a growing focus on patient-centric care are expected to enhance market opportunities further.

In Europe, the internal neuromodulation market is anticipated to witness steady growth, primarily fueled by rising healthcare awareness and the increasing number of patients seeking innovative treatment options. The region is characterized by a robust healthcare system and significant investments in medical technology, which contribute to the growth of neuromodulation therapies. Emerging markets in Asia Pacific and Latin America present tremendous growth opportunities, driven by increasing disposable incomes, improvements in healthcare infrastructure, and heightened awareness of treatment options. The internal neuromodulation market in Asia Pacific is projected to grow at a CAGR of around 9% during the forecast period, reflecting a growing demand for advanced medical treatments.

Opportunities

The internal neuromodulation market is poised for numerous opportunities as advancements in technology and awareness regarding neurological conditions continue to evolve. One significant opportunity lies in the growing investment in research and development endeavors aimed at enhancing device efficacy and safety. Manufacturers are increasingly focusing on creating innovative and minimally invasive solutions that cater to patient needs and expectations. Moreover, the rising demand for non-pharmacological treatment options for chronic pain and neurological disorders presents a lucrative opportunity for market players. By capitalizing on these trends and aligning their product offerings with patient preferences, companies can position themselves favorably in the competitive landscape.

Emerging markets represent another substantial opportunity for growth within the internal neuromodulation market. As healthcare access improves and disposable incomes rise in regions such as Asia Pacific and Latin America, the demand for advanced medical treatments, including neuromodulation therapies, is expected to surge. Companies that are proactive in establishing a presence in these markets, whether through partnerships or localized manufacturing, can benefit from first-mover advantages. Additionally, increased collaborations between manufacturers and healthcare providers can foster knowledge sharing and improve patient outcomes, further enhancing market prospects.

Threats

Despite the promising growth trajectory, the internal neuromodulation market faces several threats that could impede its progress. One of the primary concerns is the increasing regulatory scrutiny surrounding medical devices, which can lead to prolonged approval processes and increased costs for manufacturers. Stricter regulations may hinder the introduction of innovative therapies into the market, affecting growth potential. Additionally, the ongoing opioid crisis and the public's evolving perception of pain management may cause challenges for the adoption of neuromodulation therapies, as patients and healthcare providers explore alternative treatment modalities.

Another potential threat is the presence of competition from alternative treatment options, including pharmacological therapies and newer non-invasive techniques. As the healthcare landscape evolves, patients may gravitate toward options that offer immediate relief or have less perceived risk. This shift in preference can result in market fragmentation and pressure on pricing for neuromodulation devices. To combat these challenges, companies must continuously innovate and demonstrate the value of their products, ensuring they remain relevant in the face of alternative treatment avenues.

Competitor Outlook

• Medtronic
• Boston Scientific
• Abbott Laboratories
• Johnson & Johnson
• NeuroPace, Inc.
• Stimwave Technologies
• Axonics Modulation Technologies, Inc.
• Cyberonics, Inc.
• SciMed Life Systems, Inc.
• Neurosigma, Inc.
• Soleo Health
• Helsinn Healthcare SA
• Inspira Technologies Oxy B.H.N. Ltd.
• Nuvectra Corporation
• Saluda Medical Pty Ltd.

The competitive landscape of the internal neuromodulation market is characterized by a diverse range of players, each striving to establish a foothold through innovation and strategic collaborations. Major companies like Medtronic and Boston Scientific lead the market due to their extensive product portfolios, advanced research capabilities, and strong brand recognition. Both companies continuously invest in clinical trials and innovative technologies to enhance the efficacy of their neuromodulation devices, aligning with the evolving needs of patients and healthcare providers. Furthermore, these industry giants are actively pursuing partnerships and acquisitions to expand their market reach and bolster their competitive advantage.

Abbott Laboratories and Johnson & Johnson also play significant roles in the internal neuromodulation market, capitalizing on their expertise in medical devices and focused research initiatives. Abbott has made notable strides in expanding its product offerings in neuromodulation, particularly in chronic pain management, while Johnson & Johnson continues to leverage its strong market presence to drive innovation in the field. Additionally, both companies are focused on enhancing patient education and outreach to improve treatment adoption rates.

Emerging companies like Axonics Modulation Technologies and Nuvectra Corporation are gaining traction in the internal neuromodulation market by introducing novel solutions that emphasize patient comfort and ease of use. These companies are leveraging advancements in technology to differentiate themselves from established players, focusing on developing minimally invasive and user-friendly devices. As competition intensifies, ongoing innovation will be crucial for all market players to ensure sustained growth and relevance in an ever-evolving landscape.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Medtronic
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Soleo Health
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 NeuroPace, Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Cyberonics, Inc.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Neurosigma, Inc.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Boston Scientific
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Johnson & Johnson
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Abbott Laboratories
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Nuvectra Corporation
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Helsinn Healthcare SA
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Stimwave Technologies
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Saluda Medical Pty Ltd.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 SciMed Life Systems, Inc.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Inspira Technologies Oxy B.H.N. Ltd.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Axonics Modulation Technologies, Inc.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Internal Neuromodulation Market, By Application
    • 6.1.1 Chronic Pain Management
    • 6.1.2 Parkinson's Disease
    • 6.1.3 Epilepsy
    • 6.1.4 Urinary Incontinence
    • 6.1.5 Gastroparesis
  • 6.2 Internal Neuromodulation Market, By Product Type
    • 6.2.1 Spinal Cord Stimulators
    • 6.2.2 Deep Brain Stimulators
    • 6.2.3 Vagus Nerve Stimulators
    • 6.2.4 Sacral Nerve Stimulators
    • 6.2.5 Gastric Electrical Stimulators
  • 6.3 Internal Neuromodulation Market, By Ingredient Type
    • 6.3.1 Titanium
    • 6.3.2 Stainless Steel
    • 6.3.3 Silicone
    • 6.3.4 Lead
    • 6.3.5 Lithium
  • 6.4 Internal Neuromodulation Market, By Distribution Channel
    • 6.4.1 Hospitals
    • 6.4.2 Specialty Clinics
    • 6.4.3 Ambulatory Surgical Centers
    • 6.4.4 Research Institutes
    • 6.4.5 Online Sales

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Internal Neuromodulation Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Internal Neuromodulation market is categorized based on

By Product Type

• Spinal Cord Stimulators
• Deep Brain Stimulators
• Vagus Nerve Stimulators
• Sacral Nerve Stimulators
• Gastric Electrical Stimulators

By Application

• Chronic Pain Management
• Parkinson's Disease
• Epilepsy
• Urinary Incontinence
• Gastroparesis

By Distribution Channel

• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
• Research Institutes
• Online Sales

By Ingredient Type

• Titanium
• Stainless Steel
• Silicone
• Lead
• Lithium

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Medtronic
• Boston Scientific
• Abbott Laboratories
• Johnson & Johnson
• NeuroPace, Inc.
• Stimwave Technologies
• Axonics Modulation Technologies, Inc.
• Cyberonics, Inc.
• SciMed Life Systems, Inc.
• Neurosigma, Inc.
• Soleo Health
• Helsinn Healthcare SA
• Inspira Technologies Oxy B.H.N. Ltd.
• Nuvectra Corporation
• Saluda Medical Pty Ltd.